Gastrointestinale Hormone

  • D. Grandt
  • V. Eysselein
  • H. Goebell
Chapter

Zusammenfassung

Der Gastrointestinaltrakt ist das größte endokrine Organ des Körpers. Seine Hormone werden aus endokrinen Zellen in der Schleimhaut des Magens, des Dünn- und Dickdarms bzw. aus dem Pankreas durch nervale Aktivität, humorale Stimuli oder durch mechanische oder chemische Reize im Rahmen der Nahrungsaufnahme freigesetzt [12, 31]. Die gastrointestinalen Hormone sind auf bestimmte für das Hormon charakteristische Bereiche des Intestinums beschränkt (Abb. 10.1). Nur Somatostatin kommt ubiquitär im Gastrointestinaltrakt vor.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Baldwin GS (1995) The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth. J Gastroenterol Hepatol 10 (2): 215–232PubMedCrossRefGoogle Scholar
  2. 2.
    Baldwin GS, Whitehead RH (1994) Gut hormones, growth and malignancy. [Review]. Baillieres Clin Endocrinol Metab 8 (1): 185–214PubMedCrossRefGoogle Scholar
  3. 2a.
    Bayliss WM, Starling EH (1902) The mechanism of pan-creatic secretion. J Physiol (London) 28: 325–353Google Scholar
  4. 3.
    Besson I, Ingrand P, Person B, Boutroux D, Heresbach D et al. (1995) Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 333 (9): 555–560PubMedCrossRefGoogle Scholar
  5. 4.
    Boirivant M, Fais S, Annibale B, Agostini D, Delle Fave G, Pallone F (1994) Vasoactive intestinal polypeptide modulates the in vitro immunoglobulin A production by intestinal lamina propria lymphocytes. Gastroenterology 106 (3): 576–582PubMedGoogle Scholar
  6. 5.
    Bold RJ, Ishizuka J, Townsend CM Jr, Thompson JC (1993) Biomolecular advances in gastrointestinal hormones. Arch Surg 128 (11): 1268–1273PubMedGoogle Scholar
  7. 5a.
    Bordi C, D’Adda T, Azzoni C, Pilato FP, Caruana P (1995) Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 19 (Suppl 1): 8–19Google Scholar
  8. 6.
    Bueno L, Fioramonti J (1994) Neurohormonal control of intestinal transit. Reprod Nutr Develop 34 (6): 513–525CrossRefGoogle Scholar
  9. 7.
    Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F (1995) Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201–995). Eur J Endocrinol 132 (3): 320–325PubMedCrossRefGoogle Scholar
  10. 8.
    Chow BK (1995) Molecular cloning and functional characterization of a human secretin receptor. Biochem Biophys Res Commun 212 (1): 204–211PubMedCrossRefGoogle Scholar
  11. 9.
    Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides. 15 (4): 731–755PubMedCrossRefGoogle Scholar
  12. 10.
    Dietrich JB (1994) Neuropeptides, antagonists and cell proliferation: bombesin as an example. Cell Mol Biol 40 (6): 731–746PubMedGoogle Scholar
  13. 11.
    Dimaline R, Dockray GJ (1994) Evolution of the gastrointestinal endocrine system (with special reference to gastrin and CCK). Baillieres Clin Endocrinol Metabol 8 (1): 1–24CrossRefGoogle Scholar
  14. 12.
    Dockray GJ (1994) The G. W. Harris Prize Lecture. The gut endocrine system and its control. [Review]. Exp Physiol 79 (5): 607–634PubMedGoogle Scholar
  15. 13.
    Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R (1992) Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Progr Neurobiol 38 (2): 125–167CrossRefGoogle Scholar
  16. 14.
    Eberlein GA, Eysselein VE, Schaeffer M et al. (1989) A new molecular form of PYY: structural characterization of human PYY(3–36) and PYY(1–36). Peptides 10: 797–803PubMedCrossRefGoogle Scholar
  17. 15.
    Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL et al. (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects. Regul Pept 51 (1): 63–74PubMedCrossRefGoogle Scholar
  18. 16.
    Evans TC, Crittenden SL, Kodoyianni V, Kimble J (1994) Translational control of maternal glp-1 mRNA establishes an asymmetry in the C. elegans embryo. Cell 77: 183–194PubMedCrossRefGoogle Scholar
  19. 17.
    Eysselein VE, Eberlein GA, Grandt D, Schaeffer M, Zehres B et al. (1990) Structural characterization of canine PYY. Peptides 11: 111–116PubMedCrossRefGoogle Scholar
  20. 18.
    Fahrenkrug J (1993) Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 72 (6): 354–363PubMedCrossRefGoogle Scholar
  21. 19.
    Fehmann HC, Goke R, Goke B (1995) Cell and molecular 36. biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16 (3): 390–410PubMedGoogle Scholar
  22. 19a.
    Freston JW, Borch K, Brand SJ et al. (1995) Effects of 37. hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis. Digest Dis Sci 40 (Suppl 2): 50S–62SPubMedCrossRefGoogle Scholar
  23. 20.
    Garrett NE, Mapp PI, Cruwys SC, Kidd BL, Blake DR(1992) Role of substance P in inflammatory arthritis. Ann Rheum Dis 51 (8): 1014–1018PubMedCrossRefGoogle Scholar
  24. 21.
    Glasbrenner B, Dominguez-Munoz E, Riepl RL, Vetsi A, Malfertheiner P (1995) Cholecystokinin and pancreatic 39. polypeptide release in diabetic patients with and without autonomic neuropathy. Dig Dis Sci 40 (2): 406–411PubMedCrossRefGoogle Scholar
  25. 22.
    Grandt D, Burckhardt B, Schimiczek M et al. (1992) Human PYY 3–36 inhibits gastric acid secretoin (gas) in man. Regul Pept 40 (2): 158CrossRefGoogle Scholar
  26. 23.
    Grandt D, Layer P, Rippel K et al. (1992) Peptide YY (PYY) inhibits endogenously stimulated pancreatic enzyme secretion in man. Regul Pept 40 (2): 160CrossRefGoogle Scholar
  27. 24.
    Grandt D, Teyssen S, Schimiczek M, Reeve JRJ, Feth F et al. (1992) Novel generation of hormone receptor specifi-city by amino terminal processing of peptide YY. Biochem Biophys Res Commun 186: 1299–1306PubMedCrossRefGoogle Scholar
  28. 25.
    Grandt D, Dahms P, Schimiczek M, Eysselein VE, Reeve JR Jr, Mentlein R (1993) Proteolytisches Processing durch Dipeptidyl-Aminopeptidase IV generiert Rezeptorselektivität für PYY (PYY). Med Klinik 88: 143–145Google Scholar
  29. 26.
    Guelrud M, Rossiter A, Souney PF, Rossiter G, Fanikos J, Mujica V (1992) The effect of vasoactive intestinal poly-peptide on the lower esophageal sphincter in achalasia. Gastroenterology 103 (2): 377–382PubMedGoogle Scholar
  30. 27.
    Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (736)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326 (20): 1316–1322PubMedCrossRefGoogle Scholar
  31. 28.
    Harding RK, McDonald TJ (1989) Identification and characterization of the emetic effects of peptide YY. Peptides 10: 21–24PubMedCrossRefGoogle Scholar
  32. 29.
    Hazelwood RL (1993) The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med 202 (1): 44–63PubMedGoogle Scholar
  33. 30.
    Holst JJ (1994) Glucagonlike peptide 1: a newly discov-ered gastrointestinal hormone. Gastroenterology 107 (6): 1848–1855PubMedGoogle Scholar
  34. 31.
    Holst JJ, Schmidt P (1994) Gut hormones and intestinal function. Baillieres Clin Endocrinol Metab 8 (1): 137–164PubMedCrossRefGoogle Scholar
  35. 32.
    Imperiale TF, Teran JC, McCullough AJ (1995) A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. Gastroenterology 109 (4): 1289–1294PubMedCrossRefGoogle Scholar
  36. 33.
    Jiang S, Ulrich C (1995) Molecular cloning and functional expression of a human pancreatic secretin receptor. Biochem Biophys Res Commun 207 (3): 883–890PubMedCrossRefGoogle Scholar
  37. 34.
    Jin HO, Song CW, Chang TM, Chey WY (1994) Roles of gut hormones in negative-feedback regulation of pancre-atic exocrine secretion in humans. Gastroenterology 107 (6): 1828–1834PubMedGoogle Scholar
  38. 35.
    Jule Y (1993) Enkephalins and nervous system control of intestinal motility. [French]. Arch Int Physiol Biochimie Biophys 101 (4): A49–50CrossRefGoogle Scholar
  39. 36.
    Krenning EP, Kwekkeboom DJ, de Jong M et al. (1994) Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide. Semin Oncol 21 5 (Suppl 13): 6–14Google Scholar
  40. 37.
    Krenning EP, Kwekkeboom DJ, Oei HY et al. (1994) Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing’s syndrome. Digestion 55 (Suppl 3): 54–59PubMedCrossRefGoogle Scholar
  41. 38.
    Kubota M, Nakamura T, Motokura T, Mori S, Nishida A (1994) Erythromycin improves gastrointestinal motility in extremely low birthweight infants. Acta Paediatr Jap 36 (2): 198–201Google Scholar
  42. 39.
    Lamberts SW, Chayvialle JA, Krenning EP (1993) The visualization of gastroenteropancreatic endocrine tumors. Digestion 54 (Suppl 1): 92–97PubMedCrossRefGoogle Scholar
  43. 40.
    Liddle RA (1995) Regulation of cholecystokinin secretion by intraluminal releasing factors. Am J Physiol 269 (3Pt1): G319–327PubMedGoogle Scholar
  44. 40a.
    Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA (1985) Cholecystokinin bioactivity in human plasma: molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75: 1144–1152PubMedCrossRefGoogle Scholar
  45. 41.
    Lieverse RJ, Jansen JB, Masclee AA, Lamers CB (1994) Role of cholecystokinin in the regulation of satiation and satiety in humans. Ann N Y Acad Sci 713: 268–272PubMedCrossRefGoogle Scholar
  46. 42.
    Lu Y, Owyang C (1995) Secretin at physiological doses inhibits gastric motility via a vagal afferent pathway. Am J Physiol 268 (6Pt1): G1012–6Google Scholar
  47. 43.
    McCready VR, Hickish TF (1994) Somatostatin imaging function [comment]. Lancet 343 (8898): 617PubMedCrossRefGoogle Scholar
  48. 44.
    Modlin IM, Basson MD (1993) Clinical applications of gastrointestinal hormones. Endocrinol Metab Clin North Am 22 (4): 823–844PubMedGoogle Scholar
  49. 45.
    Mortazavi P, Mueller BA (1992) Erythromycin in gastrointestinal motility disturbances. Ann Pharmacother 26 (9): 1095–1097PubMedGoogle Scholar
  50. 46.
    Muff R, Born W, Fischer JA (1995) Calcitonin, calcitonin gene-related peptide, adrenomedullin and amylin: homologous peptides, separate receptors and overlapping biological actions. Eur J Endocrinol 133 (1): 17–20PubMedCrossRefGoogle Scholar
  51. 47.
    Nielsen FC, Rehfeld JF (1994) Measurement of gut hormone gene expression: mRNA and peptides. Baillieres Clin Endocrinol Metab 8 (1): 25–49PubMedCrossRefGoogle Scholar
  52. 48.
    Otsuka M, Yoshioka K (1993) Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73 (2): 229–308PubMedGoogle Scholar
  53. 49.
    Patel YC, Srikant CB (1994) Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5). Endocrinology 135 (6): 2814–2817PubMedCrossRefGoogle Scholar
  54. 50.
    Patel DR, Kong Y, Sreedharan SP (1995) Molecular cloning and expression of a human secretin receptor. Mol Pharmacol 47 (3): 467–473PubMedGoogle Scholar
  55. 51.
    Pearson RK, Anderson B, Dixon JE (1993) Molecular biology of the peptide hormone families. Endocrinol Metab Clin North Am 22 (4): 753–774PubMedGoogle Scholar
  56. 52.
    Pedrazzini T, Brunner HR, Waeber B (1993) Neuropeptide Y and cardiovascular regulation. Curr Opinion Nephrol Hyperten 2 (1): 106–113CrossRefGoogle Scholar
  57. 53.
    Peeters TL (1993) Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105 (6): 1886–1899PubMedGoogle Scholar
  58. 54.
    Peeters TL, Muls E, Janssens J, Urbain JL, Bex M et al. (1992) Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Gastroenterology 102 (1): 97–101PubMedGoogle Scholar
  59. 55.
    Pennathur A, Cioppi M, Fayad JB, Little AG (1993) Erythromycin, motilin, and the esophagus. Surgery 114 (2): 295–299PubMedGoogle Scholar
  60. 56.
    Pennathur A, Tran A, Cioppi M, Fayad J, Sieren GL, Little AG (1994) Erythromycin strengthens the defective lower esophageal sphincter in patients with gastroesophageal reflux disease. Am J Surg 167 (1): 169–173PubMedCrossRefGoogle Scholar
  61. 57.
    Redfern JS, O’Dorisio TM (1993) Therapeutic uses of gastrointestinal peptides. Endocrinol Metab Clin North Am 22 (4): 845–873PubMedGoogle Scholar
  62. 58.
    Reeve JR Jr, Eysselein VE, Ho FJ, Chew P, Vigna SR et al. (1994) Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology. Ann N Y Acad Sci 713: 11–21PubMedCrossRefGoogle Scholar
  63. 59.
    Schjoldager BT (1994) Role of CCK in gallbladder function. Ann N Y Acad Sci 713: 207–218PubMedCrossRefGoogle Scholar
  64. 60.
    Sharkey KA (1992) Substance P and calcitonin gene-related peptide (CGRP) in gastrointestinal inflammation. Ann N Y Acad Sci 664: 425–442PubMedCrossRefGoogle Scholar
  65. 61.
    Shulkes A (1994) Somatostatin: physiology and clinical applications. Baillieres Clin Endocrinol Metab 8 (1): 215–236PubMedCrossRefGoogle Scholar
  66. 62.
    Simon DM, Cello JP, Valenzuela J, Levy R, Dickerson G et al. (1995) Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-asso-ciated diarrhea. Gastroenterology 108 (6): 1753–1760PubMedCrossRefGoogle Scholar
  67. 63.
    Spindel ER, Giladi E, Segerson TP, Nagalla S (1993) Bornbesin-like peptides: of ligands and receptors. Rec Prog Horm Res 48: 365–391PubMedGoogle Scholar
  68. 64.
    Stanfa L, Dickenson A, Xu XJ, Wiesenfeld-Hallin Z (1994) Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 15 (3): 65–66PubMedCrossRefGoogle Scholar
  69. 65.
    Tack J (1995) Georges Brohee Prize 1994. Motilin and the enteric nervous system in the control of interdigestive and postprandial gastric motility. Acta Gastroenterologica Belgica. 58 (1): 21–30Google Scholar
  70. 66.
    Taylor SD, Soudah HC, Chey WY, Scheiman JM (1994) Duodenal acidification and secretin, but not intraduodenal fat, inhibit human gastric acid secretion via prostaglandins. Gastroenterology 107 (6): 1680–1685PubMedGoogle Scholar
  71. 67.
    Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CMB et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 (6560): 69–72PubMedCrossRefGoogle Scholar
  72. 68.
    Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S et al. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331 (17): 1116–1121PubMedCrossRefGoogle Scholar
  73. 69.
    Waeber G, Thompson N, Waeber B, Brunner HR, Nicod P, Grouzmann E (1993) Neuropeptide Y expression and regulation in a differentiated rat insulin-secreting cell line. Endocrinology 133: 1061–1067PubMedCrossRefGoogle Scholar
  74. 70.
    Waldum HL, Brenna E, Kleveland PM, Sandvik AK (1995) Gastrin-physiological and pathophysiological role: clinical consequences. Dig Dis 13 (1): 25–38PubMedCrossRefGoogle Scholar
  75. 71.
    Walsh JH (1992) Physiology and pathophysiology of gastrin. Mount Sinai J Med 59 (2): 117–124Google Scholar
  76. 72.
    Weber FH Jr, Richards RD, McCallum RW (1993) Erythromycin: a motilin agonist and gastrointestinal pro-kinetic agent. Am J Gastroenterol 88 (4): 485–490PubMedGoogle Scholar
  77. 73.
    Wettstein JG, Bueno L, Junien JL (1994) CCK antagonists: pharmacology and therapeutic interest. Pharmacol Ther 62 (3): 267–282PubMedCrossRefGoogle Scholar
  78. 74.
    Wettstein JG, Earley B, Junien JL (1995) Central nervous system pharmacology of neuropeptide Y. Pharmacol Ther 65 (3): 397–414PubMedCrossRefGoogle Scholar
  79. 75.
    Williams JA, Blevins GT Jr (1993) Cholecystokinin and regulation of pancreatic acinar cell function. Physiol Rev 73 (4): 701–723PubMedGoogle Scholar
  80. 76.
    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7–36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1): 327–332PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • D. Grandt
  • V. Eysselein
  • H. Goebell

There are no affiliations available

Personalised recommendations